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AbsTrACT
background the use of bilateral internal thoracic 
arteries (Bita) for coronary artery bypass grafting (caBg) 
may improve survival compared with caBg using single 
internal thoracic arteries (sita). We assessed the long-
term costs of Bita compared with sita.
Methods Between June 2004 and December 2007, 
3102 patients from 28 hospitals in seven countries 
were randomised to caBg surgery using Bita (n=1548) 
or sita (n=1554). Detailed resource use data were 
collected from the initial hospital episode and annually 
up to 5 years. the associated costs of this resource use 
were assessed from a UK perspective with 5 year totals 
calculated for each trial arm and pre-selected patient 
subgroups.
results total costs increased by approximately £1000 
annually in each arm, with no significant annual 
difference between trial arms. cumulative costs per 
patient at 5-year follow-up remained significantly higher 
in the Bita group (£18 629) compared with the sita 
group (£17 480; mean cost difference £1149, 95% ci 
£330 to £1968, p=0.006) due to the higher costs of the 
initial procedure. there were no significant differences 
between the trial arms in the cost associated with 
healthcare contacts, medication use or serious adverse 
events.
Conclusions higher index costs for Bita were still 
present at 5-year follow-up mainly driven by the higher 
initial cost with no subsequent difference emerging 
between 1 year and 5 years of follow-up. the overall 
cost-effectiveness of the two procedures, to be assessed 
at the primary endpoint of the 10-year follow-up, will 
depend on composite differences in costs and quality-
adjusted survival.
Trial registration number isrctn46552265
InTroduCTIon
Coronary artery bypass grafting (CABG) is one of 
the most commonly performed operations glob-
ally and an established and effective treatment for 
symptomatic multivessel coronary artery disease.1 
The routine surgical practice has been to graft a 
single internal thoracic artery (SITA) to the left 
anterior descending coronary artery and the use 
of vein or radial-artery grafts to bypass other coro-
nary arteries.2 The excellent outcomes of SITA have 
stimulated interest in the use of bilateral internal 
thoracic arteries (BITA).3 
Existing evidence from observational studies of 
the effect of BITA on long-term survival suggests 
that BITA is associated with a reduction in mortality 
compared with SITA. A recent meta-analysis of 
observational studies from nine eligible studies 
including 15 583 patients with mean follow-up 
exceeding 9 years estimated a Hazard Ratio (HR) 
of 0.79 (95% CI 0.75 to 0.84) for BITA compared 
with SITA.4 However, BITA has not been widely 
adopted due to it being a more complex proce-
dure, associated with a higher risk of sternal wound 
complications and a lack of randomised evidence 
of benefit.
The Arterial Revascularisation Trial (ART) was 
designed to address these concerns, with a primary 
objective of comparing 10-year survival rates asso-
ciated with BITA over SITA. ART has reported 
clinical and safety outcomes across trial arms at 
5 years postrandomisation.5 CABG is a high-volume 
procedure, with approximately 20 000 carried out 
in England every year; therefore, it is important 
to consider the long-term impact on costs as well 
as clinical effectiveness. ART was designed with 
an integrated health economic evaluation and will 
ultimately report on the cost-effectiveness of BITA 
versus SITA at 10 years. A 1-year cost comparison 
has previously been published, showing BITA to 
be associated with 9% higher costs, primarily due 
to longer time in theatre and in-hospital stay, and 
slightly higher costs related to sternal wound prob-
lems during follow-up.6 However, it is possible 
that these differences are offset in the long run. This 
paper investigates this possibility by providing a 
comparison of resource use and costs up to 5 years 
postrandomisation.
MeThod
Details of the ART protocol, baseline data, 1-year 
safety outcomes and 5-year clinical and safety 
outcomes have been published previously.5 7 ART 
is a multicentre randomised control trial involving 
28 hospitals across seven countries with a primary 
outcome of all-cause mortality at 10 years of 
follow-up. The trial complied with the Declaration 
of Helsinki. Prior ethics approval was obtained at 
all the participating centres and each patient was 
required to provide written informed consent.
Patients were eligible for the trial if they had 
multivessel coronary artery disease and were sched-
uled to undergo CABG as part of their routine 
care plan (this included patients requiring urgent 
surgery, but not those with evolving myocardial 
infarction). Patients requiring only single grafts or 
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concomitant valve surgery, as well as those with a history of 
CABG, were excluded. Patients were followed up at a routine 
clinical visit 6 weeks postsurgery and then annually by telephone 
call and postal questionnaires.
Measurement of resource use
The cost analysis of the two interventional strategies followed 
the general methods published previously but extended the 
analysis to assess resource costs at the 5-year follow-up on all 
patients. Information was collected at each annual follow-up 
on medication use, subsequent sternal wound complications, 
serious adverse events, the frequency of visits to a general prac-
titioner (GP), practice nurse, hospital outpatient clinic or cardiac 
rehabilitation clinic, and duration of any hospital readmission.
Measurement of costs
Costs were evaluated from the perspective of the English National 
Health Service (NHS). Clinical events and resource use during 
the initial hospital stay were costed using sources, methods 
and assumptions published previously,6 with all costs updated 
to 2016/2017 prices using the hospital and community health 
services index.8 All resources used over the remaining 5 years 
of follow-up were costed using the appropriate 2016/2017 unit 
costs.
Details of the costing methodology can be found in the 
online supplementary material of the 1-year analysis.6 Following 
this methodology, GP and practice nurse visits were costed using 
Personal Social Services Research Unit estimates applied to all 
reported visits, and NHS reference costs provided unit costs 
for all recorded hospital outpatient clinic and cardiac rehabili-
tation clinic visits. Out-of-pocket costs, such as travel costs and 
time spent on GP visits, were not collected as the perspective 
of the analysis was the healthcare system. Costs associated with 
the clinical events of myocardial infarction, cerebrovascular 
accidents, further CABG, percutaneous coronary interventions 
(PCI) or cardiac catheterisations were obtained from appropriate 
2016/2017 NHS Reference Costs. Reference costs were adjusted 
for clinical events occurring during the index admission to avoid 
double counting. The most frequent diagnosis groups classified 
as ‘other’ included musculoskeletal, gastrointestinal, cardiac 
arrhythmias and genitourinary. The cost impact of these events 
was assumed to be captured by costing the length of stay of the 
admission. An emergency department attendance was assumed 
where participants were admitted for an event, but no overnight 
stay was reported. Individual drug usage was costed using unit 
costs from the NHS electronic Market Information Tool. Full 
details of the sources and assumptions used in the costings can 
be found in the online supplementary table 1.
Missing data
Some items of data were missing as a result of incomplete 
responses or loss to follow-up. Descriptive analysis revealed 
that 70% of observations in each arm of the trial provided 
complete data for all resources used across the follow-up period. 
Logit models of missingness on baseline variables indicated that 
having some missing data was statistically significantly associ-
ated with baseline hospital, smoking status and sex. This suggests 
that the data are not missing completely at random as is assumed 
in complete case analysis. Therefore, multiple imputation was 
used to impute missing resource use in the trial data to limit 
the loss of power and bias arising from the exclusion of missing 
data; unit costs were then attached to the imputed resource use 
data.
Imputation was implemented separately by randomised treat-
ment allocation. Missing data were imputed at the most disag-
gregated level at which the model would converge. Chained 
equations using predictive mean matching or logistic regression 
were used to impute missing values for each variable.9 Imputa-
tion was conducted using the baseline hospital, age, sex, baseline 
Canadian Cardiovascular Society (CCS) class, diabetes, smoking 
status and peripheral arterial disease. Following the rule of 
thumb that the number of imputations should be at least equal 
to the percentage of incomplete cases (30%),9 the procedure was 
repeated 30 times to produce 30 imputed datasets with Rubin’s 
Rule used to summarise across imputations.10
Statistical analysis of imputed data summarised continuous 
data using means and categorical data using percentages. In 
line with recommended practice in cost analyses,11 we report 
mean costs, but also report median values for total costs in the 
online supplementary table 11. Two-sample t-tests were used for 
comparisons of mean differences and 95% CIs for differences 
were calculated. Standard errors were adjusted to account for 
clustering at the hospital level. All data analyses were performed 
using STATA 14.
sensitivity analyses
The robustness of estimates to the imputation of missing data 
was explored by analysing the costs of a complete case sample. 
In addition, the robustness of estimates including only patients 
who received the surgery they were allocated was investigated. 
Uncertainty surrounding individual unit costs is not reported, as 
the low and multiple unit costs and infrequency of many clinical 
events meant that extreme changes in assumptions were required 
to produce even modest effects on results.
subgroup analyses
Total annual cost at each time point and total cumulative costs 
were compared between BITA and SITA arms for selected 
pre-specified subgroups. These were: insulin-dependent diabetic, 
non-insulin dependent diabetic and non-diabetic, age ≥70 years 
versus <70 years, on-pump versus off-pump, prior myocardial 
infarction versus no prior myocardial infarction, New York Heart 
Association (NYHA) class I and II versus NYHA class III and IV, 
and CCS class 0, I and II versus CCS class III and IV. Five-year 
costs were also compared in each of the three countries (UK, 
Poland and Australia) which recruited >100 patients to the trial.
resulTs
Table 1 shows annual resource use and the frequency of adverse 
events by the two trial arms. Similar levels of resource use and 
counts of adverse events were observed in each trial arm at 
each time point. The two trial arms had similar frequencies of 
GP visits, nurse visits, outpatient visits, cardiac rehabilitation 
visits and nights in hospital at each time point. This resulted 
in there being no significant differences in cumulative health-
care contacts across 5 years of follow-up. Similar proportions of 
participants experienced an adverse event in each trial arm for 
the counts of myocardial infarction, cerebrovascular accident, 
major bleeds and deaths from any cause, whereas significantly 
more sternal wound problems and ‘other’ adverse events were 
reported in the BITA arm across 5 years of follow-up.
Table 2 shows the corresponding mean costs of resource use in 
each trial arm and by year of follow-up. No significant difference 
was observed for the cost of visits or hospitalisations (in total or 
by sub-category), or total medication usage. The only adverse 
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events with a significant difference in costs were sternal wound 
problems.
Table 3 and figure 1 show the mean cumulative costs for each 
year and each trial arm, and the mean difference. The index 
hospitalisation had a total cost of £12 485 in the SITA group 
compared with £13 312 in the BITA group with a significant 
difference of £827 (95% CI £261 to £1392, p<0.004). Annual 
costs increased in each arm by approximately £1000 annually, 
with no evidence of the mean difference that had emerged by 
the end of year one changing significantly over time. By year 
5, cumulative costs were on average £1149 higher in the BITA 
group than the SITA group (95% CI £330 to £1968, p<0.006). 
This difference was mainly due to the higher cost of the initial 
procedure.
Table 4 shows total costs to the 5-year follow-up for the 
various prespecified subgroup analyses and the country compar-
isons. The difference between the trial arms was found to vary 
by subgroup, with the largest differences being observed when 
separating patients by baseline diabetes history. Compared with 
the cumulative mean difference in total costs of £1149 across 
all patients, mean additional costs in the BITA arm were £5673 
higher (95% CI £1334 to £10 012, p<0.011) for patients who 
were insulin-dependent, but non-significantly higher (£681, 
95% CI -£227 to £1590, p<0.142) for patients who were 
without diabetes. Figure 2 shows how these differences evolved 
over the first 5 years of the trial. Table 4 also shows that differ-
ences in costs between the trial arms were somewhat larger for 
patients with a history of myocardial infarction, more severe 
angina or cardiac disease compared with those with no history, 
for on-pump compared with off-pump patients, for CCS class 
Table 3 Mean cumulative total costs (£) from index admission to 
the 5-year follow-up
sITA
(n=1554)
bITA
(n=1548) bITA vs sITA
Index 12 485 13 312 827 (261 to 1392; 0.004)
Year 1 14 370 15 548 1178 (503 to 1854; 0.001)
Year 2 15 214 16 342 1128 (419 to 1837; 0.002)
Year 3 15 919 17 127 1209 (471 to 1947; 0.001)
Year 4 16 669 17 878 1209 (436 to 1981; 0.002)
Year 5 17 480 18 629 1149 (330 to 1968; 0.006)
SITA, single internal thoracic artery; BITA, bilateral internal thoracic artery.
Figure 1 Mean cumulative total cost and mean annual follow-up costs. 
Table 4 Total costs (£) to the 5-year follow-up by trial arm and by 
subgroups
sITA
Mean 
cost
bITA
Mean 
cost
bITA vs sITA
Mean difference (95% CI to 
P values)
No history of diabetes 
(n=2368)
17 269 17 951 681 (−227 to 1590; 0.142)
Insulin-dependent diabetes 
(n=174)
18 355 24 028 5673 (1334 to 10012; 0.011)
Non-insulin-dependent 
diabetes (n=560)
17 957 19 403 1447 (−474 to 3367; 0.140)
Aged <70 years (n=2271) 16 474 17 842 1368 (538 to 2198; 0.001)
Aged ≥70 years (n=831) 20 042 20 666 623 (−1398 to 2644; 0.545)
Off-pump (n=1259) 17 905 18 065 160 (−1237 to 1557; 0.823)
On-pump (n=1819) 17 256 19 214 1958 (985 to 2931; 0.000)
No prior MI (n=1800) 17 222 18 088 866 (−150 to 1882; 0.095)
Prior MI (n=1300) 17 746 19 260 1514 (187 to 2840; 0.025)
NYHA class I and II 
(n=2431)
17 556 18 296 740 (−132 to 1612; 0.096)
NYHA class III and IV 
(n=669)
17 039 19 582 2542 (534 to 4550; 0.013)
CCS class 0 to I, II (n=2143) 17 571 18 185 614 (−347 to 1575; 0.210)
CCS class III to IVa/b/c 
(n=959)
17 175 19 452 2278 (769 to 3786; 0.003)
UK (n=2053) 18 052 18 864 813 (−306 to 1932; 0.154)
Poland (n=606) 15 691 16 811 1120 (130 to 2109; 0.027)
Australia (n=192) 19 878 21 767 1889 (−682 to 4460; 0.149)
BITA, bilateral internal thoracic artery; CCS, Canadian Cardiovascular Society; MI, 
myocardial infarction NYHA, New York Heart Association; SITA, single internal 
thoracic artery.
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III and above compared with class 0, I and II, and for patients 
in Australia. Full details of the difference between trial arms by 
subgroup are provided in the online supplementary tables 4–10 
and figures 1–6.
dIsCussIon
ART is the first and largest randomised comparison of SITA 
and BITA ever conducted and has permitted the first detailed 
comparison of costs of these procedures over a 5-year period. 
We found the significantly higher index cost of BITA (£827, 
95% CI £261 to £1392) is maintained up to the 5-year follow-up 
as a result of similar total costs observed in each arm over each 
subsequent follow-up period.
This is the first study to compare the cost of BITA and 
SITA at 5 years postsurgery. The finding of similar total costs 
following the initial procedure over a 5-year period is in contrast 
to previous studies comparing the cost-effectiveness of CABG 
and PCI, which have found differences in costs to emerge over 
a similar length of time. Evidence from the SYNTAX trial, for 
example, found that an initial difference of about $10 000 post 
index admission reduced to $5600 after 5 years of follow-up 
due lower revascularisation rates and medication usage in the 
CABG group.12 It is possible that differences between BITA and 
SITA may eventually emerge due to the superior long-term graft 
patency achieved with arterial grafts.
Higher cumulative costs of BITA compared with SITA at 5 
years were found to be particularly marked in patients who were 
insulin-dependent compared with those who were non-insulin 
dependent or were without diabetes. The online supplementary 
table 4 shows that this difference was primarily driven by higher 
outpatient costs, longer stays in hospital and costs associated 
with sternal wound problems, which are well recognised to be 
more frequent in patients with diabetes. Indeed, several observa-
tional studies have found diabetes and BITA to be independent 
risk factors for sternal wound infections following CABG.13 14 
However, a recent observational study found BITA to only be an 
independent predictor in patients with chronic complications of 
diabetes mellitus.15
Differences in costs also varied by surgical technique, with 
higher mean total costs observed for BITA patients who under-
went on-pump CABG while no significant difference was 
observed for patients who underwent off-pump CABG. This 
difference in costs was primarily driven by the higher cost of 
the index admission of BITA patients who underwent on-pump 
CABG. This finding compliments those of CORONARY (the 
CABG off or On Pump Revascularization Study), which showed 
no significant difference in 5-year total costs (mean difference 
$115, 95% CI -$697 to $927) between patients who underwent 
off-pump or on-pump CABG.16
The analysis in this paper is based on the randomised compar-
ison of BITA and SITA ever conducted, which reduces the poten-
tial of bias arising from unobserved factors. Our findings are 
in contrast to a recent retrospective study comparing BITA and 
SITA using a large US observational sample, which found lower 
costs for BITA and a shorter length of stay during the index 
admission.15 These differences may be the result of bias arising 
from unobserved heterogeneity between patients in the non-ran-
domised study.
The analysis in this paper assumed missing data to be MAR 
with predictions based on the resource use of similar patients 
without missing data. It is not possible to validate this assump-
tion; however, sensitivity analysis can explore how the results 
are affected if data were assumed to be missing not at random. 
Following the recommendation of Faria et al,17 this was achieved 
by shifting imputed data by a sensitivity parameter to give a 
dataset imputed under MNAR. The included values of the sensi-
tivity parameter varied imputed costs between −30% and 30% 
at 5% point intervals. The results from this analysis are shown in 
the online supplementary figure 9, which found that the differ-
ence in mean cost at the 5-year follow-up varied between £950 
and £1350.
Figure 2 Differences in mean total costs (BITA vs SITA, 95% CI) by baseline history of diabetes over time. BITA, bilateral internal thoracic 
artery; SITA, single internal thoracic artery. 
 o
n
 29 April 2019 by guest. Protected by copyright.
http://heart.bmj.com/
H
eart: first published as 10.1136/heartjnl-2018-313932 on 4 April 2019. Downloaded from 
7little M, et al. Heart 2019;0:1–7. doi:10.1136/heartjnl-2018-313932
Coronary artery disease
A potential limitation of the current analysis was the applica-
tion of UK-based unit costs to resource use from seven countries. 
This could systematically misestimate total costs if differences 
in relative prices between countries have resulted in systemati-
cally different patterns of resource use. However, such an effect 
would not necessarily bias the randomised comparison. The data 
and results presented here should permit analysts to conduct 
analyses from the perspective of countries other than the UK 
using appropriate local unit cost sets.
ConClusIon
The higher initial costs of BITA compared with SITA were still 
present at the 5-year follow-up, with similar levels of resource 
use each year following the index procedure. Other differences 
may emerge by the time all patients reach the 10-year follow-up, 
the relevant time-point for the primary outcome of the trial. 
Finally, in order to assess the cost-effectiveness of BITA versus 
SITA, any differences in cost will have to be viewed alongside any 
differences in quality-adjusted survival, which will be reported at 
the 10-year follow-up.
Key message
What is already known on this subject?
 ► The use of a single internal thoracic artery (SITA) for coronary 
artery bypass grafting is a safe, effective and high-volume 
procedure, but bilateral internal thoracic arteries (BITA) may 
offer improved long-term patient outcomes.
What might this study add?
 ► No randomised comparison of the long-term costs of these 
procedures has previously been published. Using data from 
the Arterial Revascularisation Trial, we showed that the higher 
index costs of BITA were still present at the 5-year follow-up 
mainly driven by the higher initial cost with no subsequent 
difference emerging between 1 year and 5 years of follow-
up. Larger differences were observed in certain patient 
subgroups, particularly diabetes versus non-diabetes.
how might this impact on clinical practice?
 ► Clinicians and healthcare policy-makers will find our results 
of value when considering the potential cost implications 
of moving from SITA to BITA. These cost estimates will also 
be required for researchers to assess the long-term cost-
effectiveness of BITA.
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